◀ Anchor ▶
Celltrion’s COVID-19 treatment has been approved by the government for the first time among domestically developed drugs.
However, it cannot be used for general mild patients except for the elderly, and there is a limitation that the effect on the mutant virus has not been identified.
Reporter Kim A-young reports.
◀ Report ▶
Celltrion’s antibody treatment’Rekironaju’ was approved as the first corona treatment in Korea.
It is the third antibody treatment in the world after Eli Lilly and Regeneron.
Rekironaju is a mass-produced antibody gene in the blood of a cure through cell culture. In phase 2 clinical trials, the recovery period of symptoms in mild and moderate patients was shortened by 3 days, showing similar efficacy to previously approved antibody treatments.
The targets for administration were limited to mild patients aged 60 years or older or high-risk patients with underlying diseases and moderate-sized adult patients with pneumonia symptoms.
It means that it is the first domestic treatment, but its limitations are clear.
There is also concern that when used in severely ill patients, it may be even more harmful due to an immune response.
[방지환/국립중앙의료원 중앙감염병병원운영센터장]
“It can be more theoretically dangerous in times when the body is damaged by an immune reaction, that is, when it becomes severe.
In addition, the price is high, and as if you are fit with a ringer, you must dilute the amount according to your weight in 250 millimeters of fluid and receive an intravenous injection for 90 minutes.
The quarantine authorities said, “We are also experimenting with treatment effects on the UK and South African mutant virus. We will be able to confirm the results next week.”
This is Ayoung Kim of MBC News.
MBC News awaits your report 24 hours a day.
▷ Phone 02-784-4000
▷ Email [email protected]
▷ KakaoTalk @mbc report